Halozyme Therapeutics (HALO) Shares are Down -0.08%

Halozyme Therapeutics (HALO) has risen sharply, recording gains of 22.64% in the past 4 weeks. However, the stock has corrected -0.08% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 23.3% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 6.13% and the 50-Day Moving Average is 14.85%.The 200 Day SMA reached 17.94%


Halozyme Therapeutics (NASDAQ:HALO): After opening at $12, the stock dipped to an intraday low of $11.68 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $12.215 and the buying power remained strong till the end. The stock closed at $12.08 for the day, a gain of 1.51% for the day session. The total traded volume was 1,977,162. The stocks close on the previous trading day was $12.08.

Halozyme Therapeutics (HALO) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $18 and the lowest price target forecast is $7. The average forecast of all the analysts is $14.19 and the expected standard deviation is $5.05.

Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.